Phase I Study To Determine The Maximally Tolerated Dose Of Oral, Daily CP-868,596 And CP-868,596 Plus AG-013736 When Given In Combination With Docetaxel Administered Every 3 Weeks To Patients With Advanced Solid Tumors
Phase 1
18 Years
N/A
18 Years
N/A
Not Enrolling
Both
Advanced Solid Tumors
Both
Advanced Solid Tumors
Trial Information
Phase I Study To Determine The Maximally Tolerated Dose Of Oral, Daily CP-868,596 And CP-868,596 Plus AG-013736 When Given In Combination With Docetaxel Administered Every 3 Weeks To Patients With Advanced Solid Tumors
Inclusion Criteria:
- Be ≥18 years old and with histologically or cytologically confirmed advanced solid
tumors refractory/resistant to currently available therapies or for which there is no
standard therapy.
- Patients with primary brain tumors are not eligible.
- Have at least one site of measurable disease.
Exclusion Criteria:
- Received chemotherapy (including targeted agents such as erlotinib), radiotherapy,
immunotherapy or any investigational therapy within 3 weeks of study entry (within 6
weeks for previous treatments with nitrosoureas or mitomycin C).
- Received tamoxifen within 4 weeks prior to study entry.
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
First-cycle Dose Limiting Toxicities
Outcome Time Frame:
2.5 years
Safety Issue:
Yes
Principal Investigator
Pfizer CT.gov Call Center
Investigator Role:
Study Director
Investigator Affiliation:
Pfizer
Authority:
United States: Food and Drug Administration
Study ID:
A5301005
NCT ID:
NCT00949624
Start Date:
December 2005
Completion Date:
June 2008
Related Keywords:
- Advanced Solid Tumors
- PDGFr Inhibition;
- VEGFr inhibition;
- targeted therapy
- Neoplasms
Name | Location |
|---|---|
| Pfizer Investigational Site | Asheville, North Carolina 28801 |
